Literature DB >> 8912503

Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness.

K G Saag1, L A Criswell, K M Sems, M D Nettleman, S Kolluri.   

Abstract

OBJECTIVE: To perform a systematic literature review and meta-analysis of the effectiveness of low-dose corticosteroids in the treatment of rheumatoid arthritis (RA).
METHODS: After identifying all relevant studies meeting preselected inclusion criteria, we performed 2 meta-analyses. First, we compared the effectiveness of prednisone to placebo and active drug controls (aspirin, chloroquine, or deflazacort) using standard meta-analysis methods for continuous data. Then, to compare the relative effectiveness of prednisone to second-line agents, we used methods similar to prior meta-analyses of second-line agents for RA treatment. Outcomes assessed were the number of tender and swollen joints, grip strength, and the erythrocyte sedimentation rate (ESR).
RESULTS: Very few studies directly assessed the effectiveness of corticosteroids for RA treatment, and many were of poor methodologic quality. Only 9 of 34 studies identified by our search met criteria for inclusion. The results of our standard meta-analysis indicated that corticosteroids appeared to be more effective than either placebo or active drug controls in improving most conventional outcome measures (effect size 0.90 for the number of tender joints, 1.05 for the number of swollen joints, and 1.20 for the ESR). In our second comparative meta-analysis, corticosteroids were nearly equivalent to second-line agents previously examined in meta-analyses (combined effect size 0.82).
CONCLUSION: Based on the limited data available, during moderate-term treatment periods averaging slightly over 7 months, corticosteroids appeared to be as effective or more effective than alternative therapies in improving several common RA disease activity measures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912503     DOI: 10.1002/art.1780391107

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis].

Authors:  G Hein; T Eidner; P Oelzner; B Manger
Journal:  Med Klin (Munich)       Date:  1999-10-15

2.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

3.  Corticosteroids in rheumatoid arthritis.

Authors:  E M Dennison; C Cooper
Journal:  BMJ       Date:  1998-03-14

4.  A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.

Authors:  E H Choy; G H Kingsley; B Khoshaba; N Pipitone; D L Scott
Journal:  Ann Rheum Dis       Date:  2005-03-10       Impact factor: 19.103

Review 5.  New therapies for rheumatoid arthritis.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

6.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

Review 7.  Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Vokko P van Halm; Ben A C Dijkmans
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis.

Authors:  J R Kirwan; R Hällgren; H Mielants; F Wollheim; E Bjorck; T Persson; C Book; S Bowman; M Byron; N Cox; M Field; L Kanerud; M Leirisalo-Repo; M Malaise; A Mohammad; R Palmer; I F Petersson; B Ringertz; P Sheldon; M Simonsson; N Snowden; F Van den Bosch
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 9.  Rheumatoid arthritis.

Authors:  Karen Walker-Bone; Sarah Farrow
Journal:  BMJ Clin Evid       Date:  2007-08-01

10.  Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial.

Authors:  T Pincus; C J Swearingen; G Luta; T Sokka
Journal:  Ann Rheum Dis       Date:  2008-12-15       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.